Log In
Print this Print this

recombinant human lymphotoxin alpha-derivatives, rhLT

  Manage Alerts
Collapse Summary General Information
Company Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
DescriptionRecombinant human lymphotoxin alpha-derivatives (rhLT)
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today